Benitec Announces Positive Animal Data with Lung Cancer Drug Candidate | GenomeWeb

Benitec Biopharma last week announced that a collaborator generated preclinical data showing that the company’s expressed RNAi technology can be used to boost survival in a orthotopic mouse model of non-small cell lung cancer.

The work, which was conducted by the Children’s Cancer Institute Australia of the University of South Wales, indicated that animals treated with Benitec’s Tribetarna, which targets the beta III tubulin gene, and chemotherapy survived “significantly” longer than those receiving chemotherapy alone.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.